Practical Considerations in Analgesic Selection for Chronic Noncancer Pain

Total Page:16

File Type:pdf, Size:1020Kb

Practical Considerations in Analgesic Selection for Chronic Noncancer Pain Primary Care Pain Management in Pennsylvania: Optimizing Treatment, Minimizing Risk PRACTICAL CONSIDERATIONS IN ANALGESIC SELECTION FOR CHRONIC NONCANCER PAIN MARY LYNN MCPHERSON, PHARMD, MA, BCPS, CPE UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY . LEARNING OBJECTIVES 1. Given an actual or simulated patient with chronic noncancer pain, demonstrate consideration of patient- and drug-related variables in selecting opioid analgesics. 2. Demonstrate competence in basic opioid conversion calculations and opioid dosage titration. 3. Given an actual or simulated patient with chronic noncancer pain, recommend appropriate coanalgesic. WHAT IS PAIN? ¡ “Total” Pain (Dame Cicely Saunders) ¡ Physical (due to disease or treatments) ¡ Psychological (anger, fear of suffering, depression, past experience of illness) ¡ Social (loss of role, status, job; financial concerns, worries about future/ family, dependency) ¡ Spiritual (anger, loss of faith, finding meaning, fear of the unknown ¡ An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (IASP). ¡ “Pain is whatever the person experiencing it says it is” (McCaffery). www.iasp-pain.org/AM/Template.cfm?Sec8on=Home&Template=/CM/ContentDisplay.cfm&ContentID=8705 PATHOGENESIS OF PAIN Pain Nocicep8ve Neuropathic Central or Visceral Somac Peripheral Type of pain How patient’s describe it Analgesics Nociceptive • May be sharp or dull, often aching in nature Responds well to somatic pain • Familiar pain (e.g., toothache) primary analgesics • May be exacerbated by movement (incident pain) such as NSAIDs • Well localized and consistent with underlying lesion and opioids • Examples include metastatic bone pain, postsurgical pain, musculoskeletal pain, arthritis pain Nociceptive • Arises from distention of a hollow organ Responds well to visceral pain • Usually poorly localized, deep, squeezing and crampy primary analgesics • Often associated with autonomic sensations such as nausea, such as opioids, vomiting, diaphoresis possibly non- • May be referred (heart pain to shoulder or jaw; gallbladder opioids. pain to scapula; pancreas pain to back) • Examples include pancreatic cancer, intestinal obstruction, intraperitoneal metastasis Neuropathic • Patient struggle to describe it; it’s unfamiliar Adjuvant agents pain • They use words such as burning, electrical, numb such as • Innocuous stimuli may bring on pain (allodynia) anticonvulsants, • Patients may complain of paroxysms of electrical sensation antidepressants (lancinating or lightning pains) are primary • Examples include trigeminal neuralgia, postherpetic intervention. neuralgia, painful diabetic neuropathy WHO Pain Relief Ladder (1996) hKp://www.who.int/cancer/palliave/painladder/en/ • Non-opioid Analgesics • Adjuvant Analgesics • Opioid Analgesics ACETAMINOPHEN ¡ Other names – Tylenol, APAP, Paracetamol ¡ APAP (N-acetyl-para-aminophenol) ¡ Analgesic, antipyretic ¡ Widely available in US ¡ Legend prescription combinations – 228 ¡ OTC monotherapy and combinations – > 60 ¡ 31,580 individual NDC codes for mono and combo prescription and OTC products ¡ 28 billion doses purchased yearly in US ¡ Single ingredient OTC 8 billion doses ¡ Combination OTC 9.7 billion doses ¡ Acetaminophen / opioid combos 11 billion doses Retrieved from National Drug Code Directory database: (http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm) IMS Health, IMS National Sales Perspectives™, Year 2005, Extracted 9/06. ACETAMINOPHEN MECHANISM OF ACTION ¡ Active metabolite of phenacetin ¡ Not clearly understood; centrally active ¡ Weak COX-1 and COX-2 inhibitor ¡ Equivalent to ASA as an analgesic and antipyretic agent ¡ Lacks anti-inflammatory properties ¡ Does not affect uric acid levels ¡ Does not inhibit platelet function ¡ Role in therapy ¡ Minimal role in OA of knees; no role in low back pain Smith HS. Poten8al analgesic mechanisms of acetaminophen. Pain Physician; 2009;12:269-280. ¡ Hepatotoxicity ¡ Skin reactions ¡ Drug-Drug interactions ¡ Age-related metabolic changes ¡ Pregnancy ¡ Asthma LET’S PUT YOU TO WORK! ¡ Mr. Smith is a 74 year old man who presents in your pharmacy requesting assistance purchasing a product for his newly diagnosed osteoarthritis of the knees. ¡ His physician suggested he start acetaminophen. ¡ During the conversation it comes up that Mr. Smith drinks 3-4 beers per day, and occasionally has a shot of whiskey for good luck (once or twice a week), and he has liver impairment. ¡ Under what circumstances would you be comfortable recommending acetaminophen for this patient? A. If he stops the whiskey shots once or twice a week B. If he reduces the beer consumption to no more than 2 a day C. If he “pinky swears” he will never drink alcohol again D. You would not recommend acetaminophen at this time NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AGENTS • Diclofenac* ¡ Meloxicam • Indomethacin ¡ Fenoprofen Analgesic Antipyretic • Sulindac ¡ Flurbiprofen Anti-inflammatory • Tolmetin ¡ Ibuprofen *** Antiplatelet • Celecoxib ** ¡ Ketoprofen • Meclofenamate ¡ Naproxen • Mefenamic acid ¡ Oxaprozin • Nambumetone ¡ Etodolac • Piroxicam ¡ Ketorolac *** www.online.factsandcomparisons.com *Available as topical; **COX-2 selective; ***Available as injectable NSAID TOXICITY ¡ Gastrointestinal ¡ Perforation, ulcers, bleeding ¡ Cardiovascular/cerebrovascular ¡ MI, heart failure, CVA ¡ Renal adverse effects ¡ Decreased GFR, progression of CKD ¡ Other adverse effects • Non-opioid Analgesics • Adjuvant Analgesics • Opioid Analgesics WHO’S UP FOR AN ADJUVANT ANALGESIC? Adjuvant hKp://www.who.int/cancer/palliave/painladder/en/ WHAT IS AN ADJUVANT? ¡ What is an adjuvant? ¡ “Serving to help or assist; auxiliary.” ¡ “Serving to aid or contribute.” ¡ What is an adjuvant analgesic? ¡ “Drugs with a primary indication other than pain that have analgesic properties in some painful conditions.” ¡ “Medications whose primary indication is the treatment of a medical condition, with secondary effects of analgesia.” ¡ Also referred to as “co-analgesics” www.ask.com; www.merriam-webster.com; hKp://theoncologist.alphamedpress.org/content/9/5/571.full Am J Hospice Pall Med 2012:29(1):70-79 ADJUVANT ANALGESICS • Mul,purpose Analgesics • An8depressants, CCS, NSAIDs, α-2 adrenergic agonists, neurolep8cs • Adjuvants for Neuropathic Pain • An8convulsants, Na+ channel blockers, NMDA antagonists, cannabinoids • Topical Analgesics • Capsaicin, local anesthe8cs, NSAIDs • Adjuvants for Bone Pain • CCS, NSAIDs, calcitonin/bisphosphonates, Radiopharmaceu8cals • Other • Adjuvants for bowel obstruc8on, musculoskeletal pain Portenoy, Ahmed. hKp://www.futuremedicine.com/doi/abs/10.2217/ebo.11.340 HOLD THE PHONE! ¡ Which of the following antidepressants is LEAST likely to provide pain relief? A. Nortriptyline B. Duloxetine (Cymbalta) C. Sertraline (Zoloft) D. Venlafaxine (Effexor) PRINCIPLES OF ADJUVANT ANALGESIC USE ¡ Assess complaint of pain, determine relationship to underlying disease, consider comorbidities ¡ Depression? ¡ Avoid initiating several adjuvant analgesics concurrently ¡ Initiate treatment with low doses and titrate gradually according to analgesic response and adverse effect ¡ Select adjuvant analgesics based on knowledge of pharmacology, evidence base, interaction with other drugs, and potential adverse effects Portenoy, Ahmed. hKp://www.futuremedicine.com/doi/abs/10.2217/ebo.11.340 PRINCIPLES OF ADJUVANT ANALGESIC USE ¡ General principles of adjuvant analgesic use: ¡ Multiple pathways of pain transmission provide multiple targets of pain relief ¡ Use specific adjuvant for specific condition ¡ Titrate only one drug at a time ¡ May take several days-weeks to notice improvement in pain ¡ Adjuvants usually do not provide full pain relief ¡ Educate patients about trial-and-error nature of adjuvant use ¡ Select rational combinations of analgesics/adjuvant analgesics Portenoy, Ahmed. hKp://www.futuremedicine.com/doi/abs/10.2217/ebo.11.340 • Non-opioid Analgesics • Adjuvant Analgesics • Opioid Analgesics WHO LET THE OPIOIDS OUT? Opioids hKp://www.who.int/cancer/palliave/painladder/en/ OPIOID CATEGORIES Category Examples Phenanthrenes • Morphine • Codeine • Hydromorphone • Levorphanol • Oxycodone • Hydrocodone • Oxymorphone • Buprenorphine • Nalbuphine • Butorphanol Benzomorphans • Pentazocine Phenylpiperidines • Fentanyl, alfentanil, sufentanil • Meperidine Diphenylheptanes • Methadone • (Propoxyphene) – off market Pain Physician 2008;11:S133-S153. ATYPICAL OPIOIDS ¡ Tramadol and Tapentadol ¡ Indicated for the management of moderate to severe acute or chronic pain ¡ Tramadol: Weak mu opioid agonist, increases serotonin and norepinephrine levels ¡ Tapentadol: Mu opioid agonist and primarily inhibits reuptake of norepinephrine OPIOID INDICATIONS AND USES ¡ Analgesia ¡ Moderate to severe pain ¡ Anesthesia ¡ Cough ¡ Detoxification ¡ Diarrhea ¡ Dyspnea OPIOIDS FOR PAIN MANAGEMENT ¡ Are all painful conditions amenable to opioid treatment? ¡ Consider benefits and burdens of therapy ¡ If an opioid is appropriate, should it be monotherapy? Which opioid? When should an adjuvant be used? ¡ If an opioid is appropriate, should a tamper-resistant formulation be used? ¡ If the patient doesn’t respond to the first opioid, or has an adverse outcome, should we switch to a different opioid? ¡ Are there special considerations when switching to methadone? ¡ What is the role for adjuvant analgesics? ORAL MORPHINE FOR CANCER PAIN ¡ Effectiveness of oral morphine in treating moderate to severe cancer pain. ¡ 62 studies with 4241 participants
Recommended publications
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Neuropathic Component of Low Back Pain of Low Back Component Neuropathic +2 ) Enters Into Cell
    229 NEUROPATHIC Aspects Spine Surgery: Current Minimally Invasive COMPONENT OF LOW BACK PAIN 36 Simin Hepguler MD month study period, it was estimated that direct re- Introduction source cost was 96 million $ for patients with CLBP and neuropathic component of CLBP accounted for ow back pain is a frequent problem of mus- 96% of the total cost. Cost of care is 160% higher for culo-skeletal system. Life-long prevalence is patients with CLBP associated with NP than patient 60-85% and the incidence is 15% (12-30%) in with CLBP not associated with NP. CLBP with NP L26 adults. Although underlying cause is not known component is found in 4% of German adult popula- in most cases, compression fracture was found in tion. Care cost of neuropathic low back pain is 67% 4% of all low back pain cases, while spondylolisthe- higher than care cost of nociceptive pain. Of the to- sis, tumor or metastasis, ankylosing spondylitis and tal care cost of low back pain, 16% is reserved for infection were determined in 3%, 0.07%, 0.3% and neuropathic component.39 0.01%, respectively. It was also found that remain- ing cases were secondary to mechanical spraining of structures forming the lumbar region.26 Definition This is the most common and most expensive Low back pain is felt in a region ranging from in- reason of occupation-related disability in subjects ferior margin of rib cage to waistline; the pain can who are aged <45 years. The estimated direct cost be localized in lumbar region, but it may also radi- of the condition was 1.6 billion £ and the total cost ate to the leg.
    [Show full text]
  • Ketamine: an Update for Its Use in Complex Regional Pain Syndrome
    xperim & E en l ta a l ic P in h Bentley et al., Clin Exp Pharmacol 2015, 5:2 l a C r m f Journal of DOI: 10.4172/2161-1459.1000169 o a l c a o n l o r g u y o J ISSN: 2161-1459 Clinical and Experimental Pharmacology Commentry Open Access Ketamine: An Update for Its Use in Complex Regional Pain Syndrome and Major Depressive Disorder William E Bentley*, Michael Sabia, Michael E Goldberg and Irving W Wainer Cooper University Hospital, Camden, New Jersey, United States of America Abstract In recent years, there has been significant research in regard to the efficacy of ketamine in regards to treating Complex Regional Pain Syndrome (CRPS) and Major Depressive Disorder (MDD). Many patients have had substantial symptomatic relief; however, not all patients have had positive results. This has prompted current research with evidence to suggest certain biomarkers exist that would infer which patients will/will not respond to ketamine treatment. Current biomarkers of interest include D-Serine (D-Ser) and magnesium, which will be discussed. Whether or not D-Ser and/or magnesium levels should be checked and possibly dictate therapy is an area of future research. It is also possible that downstream metabolites of ketamine are the key to successful therapy. Keywords: Complex regional pain syndrome; Major Depressive thoughts; and slowing of speech and action. These changes must last a Disorder(MDD); Ketamine minimum of 2 weeks and interfere considerably with work and family relations” [6]. Treatment options include antidepressant medications, Complex Regional Pain Syndrome (CRPS) and Major Depressive cognitive behavioral therapy, and interpersonal therapy.
    [Show full text]
  • Nitrous Oxide in Emergency Medicine Í O’ Sullivan, J Benger
    214 ANALGESIA Emerg Med J: first published as 10.1136/emj.20.3.214 on 1 May 2003. Downloaded from Nitrous oxide in emergency medicine Í O’ Sullivan, J Benger ............................................................................................................................. Emerg Med J 2003;20:214–217 Safe and predictable analgesia is required for the identify these zones as there is considerable vari- potentially painful or uncomfortable procedures often ation between people. He also emphasised the importance of the patient’s pre-existing beliefs. If undertaken in an emergency department. The volunteers expect to fall asleep while inhaling characteristics of an ideal analgesic agent are safety, 30% N2O then a high proportion do so. An appro- predictability, non-invasive delivery, freedom from side priate physical and psychological environment increases the actions of N2O and may allow lower effects, simplicity of use, and a rapid onset and offset. doses to be more effective. Unlike many other Newer approaches have threatened the widespread use anaesthetic agents, N2O exhibits an acute toler- of nitrous oxide, but despite its long history this simple ance effect, whereby its potency is greater at induction than after a period of “accommoda- gas still has much to offer. tion”. .......................................................................... MECHANISM OF ACTION “I am sure the air in heaven must be this Some writers have suggested that N2O, like wonder-working gas of delight”. volatile anaesthetics, causes non-specific central nervous system depression. Others, such as 4 Robert Southey, Poet (1774 to 1843) Gillman, propose that N2O acts specifically by interacting with the endogenous opioid system. HISTORY N2O is known to act preferentially on areas of the Nitrous oxide (N2O) is the oldest known anaes- brain and spinal cord that are rich in morphine thetic agent.
    [Show full text]
  • Recognition and Alleviation of Distress in Laboratory Animals
    http://www.nap.edu/catalog/11931.html We ship printed books within 1 business day; personal PDFs are available immediately. Recognition and Alleviation of Distress in Laboratory Animals Committee on Recognition and Alleviation of Distress in Laboratory Animals, National Research Council ISBN: 0-309-10818-7, 132 pages, 6 x 9, (2008) This PDF is available from the National Academies Press at: http://www.nap.edu/catalog/11931.html Visit the National Academies Press online, the authoritative source for all books from the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the National Research Council: x Download hundreds of free books in PDF x Read thousands of books online for free x Explore our innovative research tools – try the “Research Dashboard” now! x Sign up to be notified when new books are published x Purchase printed books and selected PDF files Thank you for downloading this PDF. If you have comments, questions or just want more information about the books published by the National Academies Press, you may contact our customer service department toll- free at 888-624-8373, visit us online, or send an email to [email protected]. This book plus thousands more are available at http://www.nap.edu. Copyright © National Academy of Sciences. All rights reserved. Unless otherwise indicated, all materials in this PDF File are copyrighted by the National Academy of Sciences. Distribution, posting, or copying is strictly prohibited without written permission of the National Academies Press. Request reprint permission for this book. Recognition and Alleviation of Distress in Laboratory Animals http://www.nap.edu/catalog/11931.html Recognition and Alleviation of Distress in Laboratory Animals Committee on Recognition and Alleviation of Distress in Laboratory Animals Institute for Laboratory Animal Research Division on Earth and Life Studies THE NATIONAL ACADEMIES PRESS Washington, D.C.
    [Show full text]
  • Analgesic Indications: Developing Drug and Biological Products
    Guidance for Industry Analgesic Indications: Developing Drug and Biological Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact Sharon Hertz at 301-796-2280. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2014 Clinical/Medical 5150dft.doc 01/15/14 Guidance for Industry Analgesic Indications: Developing Drug and Biological Products Additional copies available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, rm. 2201 Silver Spring, MD 20993-0002 Tel: 301-796-3400; Fax: 301-847-8714; E-mail: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February
    [Show full text]
  • Diclofenac Topical Patch Gel Solution Monograph
    Diclofenac Topical Patch, Gel and Solution National Drug Monograph March 2016 VHA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Action Diclofenac is the only nonsteroidal antiinflammatory drug (NSAID) approved in the U.S. for topical application. The mechanism of diclofenac is believed to be inhibition of prostaglandin synthesis, primarily by nonselectively inhibiting cyclooxygenase. The agents covered in this review are the four diclofenac topical products approved for analgesic purposes: Diclofenac epolamine / hydroxyethylpyrrolidine patch (DEHP) 1.3% approved in January 2007 Diclofenac sodium topical gel 1%, approved in October 2007 Diclofenac sodium topical solution 1.5% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in November 2009 Diclofenac sodium topical solution 2% with dimethyl sulfoxide (DMSO, 45.5% w/w), approved in January 2014 Indication(s) Under Review in this document (may include off Solution 1.5% Solution 2% label) Patch 1.3% Gel 1% (Drops) (MDP) Topical treatment Relief of the pain of Treatment of signs Treatment of the Also see Table 1 Product Descriptions of acute pain due osteoarthritis of joints and symptoms of pain of below. to minor strains, amenable to topical osteoarthritis of the osteoarthritis of sprains, and treatment, such as the knee(s) the knee(s) contusions knees and those of the hands.
    [Show full text]
  • Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information
    ® Voltaren (diclofenac sodium enteric-coated tablets) Tablets of 75 mg Rx only Prescribing Information Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS.) • Voltaren® (diclofenac sodium enteric-coated tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Voltaren® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. Voltaren is available as delayed-release (enteric-coated) tablets of 75 mg (light pink) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in Voltaren include: hydroxypropyl methylcellulose, iron oxide, lactose, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium hydroxide, sodium starch glycolate, talc, titanium dioxide. CLINICAL PHARMACOLOGY Pharmacodynamics Voltaren® (diclofenac sodium enteric-coated tablets) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Voltaren, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
    [Show full text]
  • ACPA Guide to Pain Management
    [Document title] [Document subtitle] Abstract [Draw your reader in with an engaging abstract. It is typically a short summary of the document. When you’re ready to add your content, just click here and start typing.] ACPA [Email address] 1 ACPA Resource Guide To Chronic Pain Management An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies 2019 Edition American Chronic Pain Association P.O. Box 850 Rocklin, CA 95677 Tel 800-533-3231 Fax 916-652-8190 E-mail [email protected] Web Site http://www.theacpa.org Copyright 2019 American Chronic Pain Association, Inc. All rights reserved. No portion of this book may be reproduced without permission of the American Chronic Pain Association, Inc. 2 Table of Contents A STATEMENT FROM THE ACPA BOARD OF DIRECTORS ...........................................................................................................................5 INTRODUCTION ........................................................................................................................................................................................................6 OVERVIEW OF CHRONIC PAIN TREATMENT ..................................................................................................................................................8 WHAT DOES SUCCESSFUL PAIN TREATMENT LOOK LIKE? .......................................................................................................................8 PAIN TYPES, SOURCES & CLASSIFICATION .....................................................................................................................................................9
    [Show full text]
  • Use of Non-Opioid Analgesics As Adjuvants to Opioid Analgesia for Cancer Pain Management in an Inpatient Palliative Unit: Does T
    Support Care Cancer (2015) 23:695–703 DOI 10.1007/s00520-014-2415-9 ORIGINAL ARTICLE Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? Shivani Shinde & Pamela Gordon & Prashant Sharma & James Gross & Mellar P. Davis Received: 2 October 2013 /Accepted: 18 August 2014 /Published online: 29 August 2014 # Springer-Verlag Berlin Heidelberg 2014 Abstract morphine equivalent doses of the opioid in both groups (median Background Cancer pain is complex, and despite the intro- (min, max); 112 (58, 504) vs. 200 (30, 5,040)) at the time of duction of the WHO cancer pain ladder, few studies have discharge; 75–80 % of patients had improvement in pain scores looked at the prevalence of adjuvant medication use in an as measured by a two-point reduction in numerical rating scale inpatient palliative medicine unit. In this study, we evaluate (NRS). the use of adjuvant pain medications in patients admitted to an Discussion This study shows that adjuvant medications are inpatient palliative care unit and whether their use affects pain commonly used for treating pain in patients with cancer. More scores or opiate dosing. than half of study population were on two adjuvants or an Methods In this retrospective observational study, patients adjuvant plus NSAID along with an opioid. We did not admitted to the inpatient palliative care unit over a 3-month demonstrate any benefit in terms of improved pain scores or period with a diagnosis of cancer on opioid therapy were opioid doses with adjuvants, but this could reflect confound- selected.
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • ATC CODING for MEDICATION DATA SAS DATASET NAME: Meds1 8S PROTOCOL NAME: Meds1 8S Protocol.Don
    ATC CODING FOR MEDICATION DATA SAS DATASET NAME: meds1_8s PROTOCOL NAME: meds1_8s_protocol.don Medications were coded using the World Health Organization‟s Anatomical Therapeutic Chemical (ATC) classifications. Information about the ATC classification system can be found at http://www.whocc.no/atcddd/. Briefly, The numeric ATC codes assigned to a drug can be broken down into five parts. For example in the code N02BE01: The first character (N) represents the main anatomical group. In this example N = Nervous System. Characters two and three (02) represent the therapeutic subgroup. In this example N02 = Analgesics. Character four (B) represents the pharmacological subgroup. In this example N02B = Other analgesics and antipyretics. Character five (E) represents the chemical subgroup. In this example N02BE = Anilides. Characters six and seven (01) represent the chemical substance. In this example N02BE01 = Paracetamol (acetaminophen). If a medication consists of multiple compounds, all unique compounds were coded leaving up to four codes per medication in the coded database (variable names = atc_cod1,…,atc_cod4). There were a few exceptions including oral contraceptives, vitamins/supplements and other multi-compound medications not assigned to one code per compound due to the nature of the medication. Looking at the contraceptive example below, if we use the first two codes instead of one of the second two codes we lose the info about fixed or sequential doses and the fact that it is specifically an oral contraceptive: (1) G03AC03 LEVONORGESTREL
    [Show full text]